Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

In recent years, nanoparticulate-mediated drug delivery research has examined a full
spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer …

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction
therapy (primary induction failure [PIF]) or relapse after< 6 months (early relapse [ER]). We …

Liposomes are a class of well-established drug carriers that have found numerous
therapeutic applications. The success of liposomes, together with recent advancements in …

Background: Acute myeloid leukemia (AML) is a clonal disease characterized by the
proliferation and accumulation of myeloid progenitor cells in the bone marrow, which …

We evaluated the impact of salvage regimens and allogeneic hematopoietic cell
transplantation (allo-HCT) in acute myeloid leukemia (AML) with induction failure. Between …

Several nanoformulated anti-cancer substances are currently commercialized or under
development. Pre-clinical and clinical results have revealed better properties, that is, larger …

The eukaryotic translation initiation factor eIF4E is elevated in about 30% of human
malignancies including HNSCC where its levels correlate with poor prognosis. Here, we …

Background To explore the effect of low dose of homoharringtonine (HHT) and cytarabine
(Ara-c) combined with granulocyte colony-stimulating factor (G-CSF) priming (HAG regimen) …

Chidamide, a novel histone deacetylase inhibitor (HDACi), has been approved for treatment
of T-cell lymphomas in multiple clinical trials. It has been demonstrated that chidamide can …